GF
SRPT icon

Gabelli Funds’s Sarepta Therapeutics SRPT Stock Holding History

Gabelli Funds’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,000
Closed -$225K – 1373
2022
Q2 		$225K Hold
3,000
– – ﹤0.01% 1173
2022
Q1 		$234K Hold
3,000
– – ﹤0.01% 1224
2021
Q4 		$270K Hold
3,000
– – ﹤0.01% 1206
2021
Q3 		$277K Hold
3,000
– – ﹤0.01% 1183
2021
Q2 		$233K Hold
3,000
– – ﹤0.01% 1215
2021
Q1 		$224K Buy
+3,000
New +$277K ﹤0.01% 1213

Other funds holding SRPT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Gabelli Funds's SRPT Position: Q3 2022 in Review

Gabelli Funds sold out of Sarepta Therapeutics (SRPT) in Q3 2022, closing a stake of 3,000 shares — an estimated $225K sold.

Gabelli Funds first reported a position in SRPT in Q1 2021 and held it in 6 quarters. The position peaked at $277K in Q3 2021. 375 funds tracked by Wall St. Rank hold SRPT as of Q3 2022.

  • Gabelli Funds reported no remaining Sarepta Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Gabelli Funds sold 3,000 Sarepta Therapeutics shares in Q3 2022, an estimated $225K.
  • Gabelli Funds first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 6 quarters.
  • Gabelli Funds's Sarepta Therapeutics position peaked at $277K in Q3 2021.
  • 375 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2022.

Based on Gabelli Funds's 13F filing for Q3 2022, filed 10 Nov 2022.